DT
HealthMore in Health→
Experimental pancreatic cancer drug points to a rare survival gain in a hard-to-treat disease
A Northwestern-developed drug reportedly doubled one-year survival in a pancreatic cancer trial, a notable signal in one of oncology’s most difficult treatment areas.
Key Takeaways
- The supplied source says pancreatic cancer remains among the deadliest and hardest cancers to treat.
- A Northwestern-developed drug reportedly doubled one-year survival in a trial.
DE
DT Editorial Team··via medicalxpress.com